Synonyms
- Reveal® Microarray
Special Instructions
Pertinent medical findings should accompany the test request form.
Expected Turnaround Time
10 - 14 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
For more information, please view the literature below.
Chromosome Microarray: A New High-density Allele-specific Diagnostic Platform
Specimen Requirements
Specimen
Whole blood, bone marrow, or nonfixed tumor tissue
Volume
4 mL whole blood, 2 mL bone marrow, or >2 to 4 mm3 tissue
Minimum Volume
2 mL whole blood or 1 mL bone marrow for array only (Note: This volume does not allow for repeat testing.)
Container
Green-top (heparin) tube (preferred), yellow-top (ACD) tube, or lavender-top (EDTA) tube; sterile container containing sterile saline, Ringer's lactate, or Hanks' balanced salt solution or transport medium provided by the cytogenetic laboratory
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Quantity not sufficient for analysis; gel-separator tubes; microtainer tubes; fixed cell pellets
Test Details
Use
This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.
Limitations
This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only that only contain heterochromatin or tetraploidy.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
SNP microarray analysis is performed using the Cytoscan® HD Accel platform, which uses more than 743,130 SNP probes and 2,029,441 NPCN probes with a median spacing of 0.818 kb.
References
Gunnarsson R, Staaf J, Jansson M, et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia−A comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer. 2008 Aug; 47(8):697-711.18484635
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 510146 | Reveal (R) SNP CMA - Oncology | 510139 | Specimen Type | 31208-2 | ||
| 510146 | Reveal (R) SNP CMA - Oncology | 510147 | # of Genotyping Targets | N/A | ||
| 510146 | Reveal (R) SNP CMA - Oncology | 510218 | Diagnosis | 62357-9 | ||
| 510146 | Reveal (R) SNP CMA - Oncology | 510159 | Interpretation | 62365-2 | ||
| 510146 | Reveal (R) SNP CMA - Oncology | 510161 | Director Review: | 48672-0 | ||
| 510146 | Reveal (R) SNP CMA - Oncology | 512123 | 51967-8 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf